Results 11 to 20 of about 48,364 (325)
Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
Pharmaceutics, 2023 (1) Background: Solid dispersion (SD) can help increase the bioavailability of poorly water-soluble drugs. Meanwhile, apixaban (APX)—a new anticoagulation drug—has low water solubility (0.028 mg/mL) and low intestinal permeability (0.9 × 10−6 cm/s across Caco-2 colonic cells), thus resulting in a low oral bioavailability of <50%; (2) Methods: To ...
Juseung Lee +7 more
openaire +4 more sources
Apixaban and oral implications [PDF]
Journal of Clinical and Experimental Dentistry, 2015 Background: Thrombotic disorders remain a leading cause of death in the Western world, and in this regard a number of anticoagulation treatment have been used, including heparins, fondaparinux, vitamin K antagonists ...
Bagán Sebastián, José Vicente +1 more
core +7 more sources
Implications of apixaban for dental treatments [PDF]
Journal of Clinical and Experimental Dentistry, 2016 Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. Recently, new oral anticoagulants have been introduced as alternatives to warfarin and acenocoumarol.
Albaladejo Martínez, Alberto +1 more
core +5 more sources
Italian Journal of Medicine, 2013 Introduction: Thromboembolic events represent the final common mechanism in the pathogenesis of the most lethal vascular diseases in the developed countries (including acute coronary syndromes, ischemic stroke, deep vein thrombosis, and pulmonary ...
Gianluca Airoldi, Mauro Campanini
doaj +6 more sources
Apixaban as a Rare Cause of Leukocytoclastic Vasculitis [PDF]
Case Reports in Rheumatology, 2020 Apixaban is a rare cause of leukocytoclastic vasculitis (LCV). To our knowledge, there is only one other reported case due to apixaban in the literature. We present a case of apixaban-induced leukocytoclastic vasculitis in a 95-year-old male. He had been
Jenna Spears +4 more
doaj +3 more sources
Drugs, 2011 Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders. Apixaban has been approved in the EU for the prevention of venous thromboembolism (VTE) after hip or knee replacement.
Gianluca Airoldi, Mauro Campanini
openalex +4 more sources
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
New England Journal of Medicine, 2023 BACKGROUND Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators.
J. Healey +36 more
semanticscholar +1 more source
A Dangerous and Unrecognized Interaction of Apixaban [PDF]
Cureus, 2021 Direct oral anticoagulants (DOACs) drug-to-drug interactions are underrecognized by clinicians. Apixaban has cytochrome 450 (CYP) mediated metabolism (primarily by CYP3A4). Strong inducers and inhibitors of this enzyme may cause variations in the blood level of apixaban. This report presents a patient who received a femoral artery stent and developed a
Ammar, Hussam, Govindu, Rukma R
openaire +3 more sources
Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve.
NEJM Evidence, 2023 Apixaban, Warfarin, and On-X Mechanical Aortic ValvesAlthough vitamin K antagonists are the only oral anticoagulants approved with mechanical heart valves, this trial examined whether apixaban could be safely used in patients with an On-X mechanical ...
Tracy Y. Wang +24 more
semanticscholar +1 more source
Apixaban-induced liver injury [PDF]
BMJ Case Reports, 2016 An 81-year-old woman with well-controlled hypertension presented to the emergency department with new-onset atrial fibrillation with rapid ventricular response. Treatment for atrial fibrillation was initiated, including rate control and anticoagulation with 5 mg of apixaban two times per day for primary stroke prophylaxis.
Sherri-Anne Clarke +3 more
openalex +4 more sources